tsn

Pfizer’s Abrocitinib Meets Endpoints in Phase 3 JADE TEEN Study for Atopic Dermatitis

 9218
0 comment
Staff at TrialSite | Quality Journalism
Jun. 11, 2020, 8:30 p.m.

TrialSiteNews
159 W Broadway, Suite 200
Salt Lake City, UT 84101
© 2024 - Trial Site News